Literatur
-
1
Bender R, Lange S, Ziegler A.
Multiples Testen.
Dtsch Med Wochenschr.
2007;
132 Suppl 1
e26-29
-
2
Dormandy J A, Charbonnel B, Eckland D J. et al .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet.
2005;
366
1279-1289
-
3
Eckert S, Erdmann E, Lundershausen R. et al .
Positionsbestimmung zum Stellenwert von Pioglitazon in der Diabetestherapie.
Dtsch Med Wochenschr.
2007;
132
2650-2653
-
4
Freemantle N.
How well does the evidence on pioglitazone back up researchers’ claims for a reduction in macrovascular events?.
BMJ.
2005;
331
836-838
-
5
O’Neill R T.
Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance.
Control Clin Trials.
1997;
18
550-556
-
6
Proschan M A, Waclawiw M A.
Practical guidelines for multiplicity adjustment in clinical trials.
Control Clin Trials.
2000;
21
527-539
Prof. Dr. med. Wolfgang Kerner
Klinik für Diabetes und Stoffwechselerkrankungen, Klinikum Karlsburg
Greifswalder Str. 11
17495 Karlsburg
Telefon: 038355/701-397
Fax: 038355/701-582
eMail: prof.kerner@drguth.de
